Frequent Engagement of the Classical and Alternative NF-??B Pathways by Diverse Genetic Abnormalities in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.115-145, 2007. ,
DOI : 10.1016/j.ccr.2007.07.004
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma, Clinical Cancer Research, vol.15, issue.16, pp.5250-5257, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2850
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes, Nature Biotechnology, vol.276, issue.3, pp.255-65, 2011. ,
DOI : 10.1038/nprot.2007.202
Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.26, pp.6333-6341, 2005. ,
DOI : 10.1200/JCO.2005.05.021
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma, Blood, vol.102, issue.7, pp.2615-2637, 2003. ,
DOI : 10.1182/blood-2003-01-0233
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions, Science, vol.325, issue.5942, pp.834-874, 2009. ,
DOI : 10.1126/science.1175371
Statistical tests for differential expression in cDNA microarray experiments, Genome Biology, vol.4, issue.4, p.210, 2003. ,
DOI : 10.1186/gb-2003-4-4-210
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells, Blood, vol.100, issue.1, pp.194-203, 2002. ,
DOI : 10.1182/blood.V100.1.194
Vantage 088: vorinostat in combination with bortezomib in pa-tients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial, Blood, issue.118 811, 2011. ,
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling, Molecular Cancer Therapeutics, vol.7, issue.6, pp.1494-505, 2008. ,
DOI : 10.1158/1535-7163.MCT-08-0183
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-97, 2000. ,
DOI : 10.1038/sj.leu.2401632
Rules for Making Human Tumor Cells, New England Journal of Medicine, vol.347, issue.20, pp.1593-603, 2002. ,
DOI : 10.1056/NEJMra021902
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma, Blood, vol.118, issue.24, pp.6274-83, 2011. ,
DOI : 10.1182/blood-2011-03-339879
Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1), Proceedings of the National Academy of Sciences, vol.106, issue.14, pp.5604-5613, 2009. ,
DOI : 10.1073/pnas.0812101106
Genome-Wide Transcriptional Response to 5-Aza-2'-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells, Cancer Research, vol.68, issue.1, pp.44-54, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-2531
Histone deacetylase inhibitors in the treatment for multiple myeloma, International Journal of Hematology, vol.70, issue.3, pp.324-356, 2013. ,
DOI : 10.1007/s12185-013-1290-3
Advances in biology of multiple myeloma: clinical applications, Blood, vol.104, issue.3, pp.607-625, 2004. ,
DOI : 10.1182/blood-2004-01-0037
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma, Molecular Cancer Therapeutics, vol.10, issue.11, pp.2034-2076, 2011. ,
DOI : 10.1158/1535-7163.MCT-11-0433
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis, Oncol Rep, vol.26, issue.5, pp.1057-62, 2011. ,
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells, Oncogene, vol.22, issue.19, pp.2950-2959, 2003. ,
DOI : 10.1038/sj.onc.1206423
URL : https://hal.archives-ouvertes.fr/inserm-00130855
The Emerging Role of Histone Deacetylases (HDACs) in UPR Regulation, Methods in enzymology, vol.490, pp.159-74, 2011. ,
DOI : 10.1016/B978-0-12-385114-7.00010-6
Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response, The FASEB Journal, vol.26, issue.6, pp.2437-2482 ,
DOI : 10.1096/fj.11-193706
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma, Haematologica, vol.91, issue.2, pp.248-51, 2006. ,
Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma, PLoS ONE, vol.7, issue.7, 2012. ,
DOI : 10.1371/journal.pone.0042161.s007
URL : https://hal.archives-ouvertes.fr/inserm-00802686
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma, Haematologica, vol.97, issue.4, pp.622-652, 2012. ,
DOI : 10.3324/haematol.2011.046821
URL : https://hal.archives-ouvertes.fr/inserm-00727008
Promiscuous Mutations Activate the Noncanonical NF-??B Pathway in Multiple Myeloma, Cancer Cell, vol.12, issue.2, pp.131-175, 2007. ,
DOI : 10.1016/j.ccr.2007.07.003
Epigenetic modifications as therapeutic targets, Nature Biotechnology, vol.7, issue.10, pp.1069-1078, 2010. ,
DOI : 10.1038/sj.bjc.6605293
Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma, British Journal of Haematology, vol.265, issue.2, pp.156-61, 2004. ,
DOI : 10.1093/jnci/90.21.1621
Histone Deacetylase Inhibitors in Cancer Therapy, Journal of Clinical Oncology, vol.27, issue.32, pp.5459-68, 2009. ,
DOI : 10.1200/JCO.2009.22.1291
Protection of p27Kip1 mRNA by quaking RNA binding proteins promotes oligodendrocyte differentiation, Nature Neuroscience, vol.36, issue.1, pp.27-33, 2005. ,
DOI : 10.1016/S0014-4886(03)00101-8
Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression, American Journal of Hematology, vol.81, issue.3, pp.170-178, 2001. ,
DOI : 10.1002/ajh.1174
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis, Blood, vol.103, issue.5, pp.1829-1866, 2004. ,
DOI : 10.1182/blood-2003-05-1510
URL : https://hal.archives-ouvertes.fr/inserm-00130207
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications, Proceedings of the National Academy of Sciences, vol.101, issue.2, pp.540-545, 2004. ,
DOI : 10.1073/pnas.2536759100
Molecular sequelae of histone deacetylase inhibition in human malignant B cells, Blood, vol.101, issue.10, pp.4055-62, 2003. ,
DOI : 10.1182/blood-2002-11-3514
The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies, Seminars in Hematology, vol.49, issue.1, pp.33-46, 2012. ,
DOI : 10.1053/j.seminhematol.2012.05.004
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, issue.4, pp.574-82, 2011. ,
DOI : 10.3324/haematol.2010.033456
URL : https://hal.archives-ouvertes.fr/inserm-00550232
Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors, Molecular Cancer Therapeutics, vol.11, issue.12, pp.2685-92, 2012. ,
DOI : 10.1158/1535-7163.MCT-12-0721
URL : https://hal.archives-ouvertes.fr/inserm-00760269
The genetic architecture of multiple myeloma, Nature Reviews Cancer, vol.214, issue.5, pp.335-383, 2012. ,
DOI : 10.1038/nrc3257
Panobinostat for the treatment of multiple myeloma, Expert Opinion on Investigational Drugs, vol.289, issue.15, pp.733-780, 2012. ,
DOI : 10.1073/pnas.0913912107
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor, Br J Haematol, vol.143, issue.4, pp.520-551, 2008. ,
Rescue of Major Histocompatibility-DR Surface Expression in Retinoblastoma-Defective, Non-small Cell Lung Carcinoma Cells by the MS-275 Histone Deacetylase Inhibitor, Biological & Pharmaceutical Bulletin, vol.32, issue.3, pp.480-482, 2009. ,
DOI : 10.1248/bpb.32.480
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma, Cancer, vol.112, issue.2, pp.336-378, 2011. ,
DOI : 10.1002/cncr.25584
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma, Leukemia & Lymphoma, vol.96, issue.2, pp.1722-1729, 2012. ,
DOI : 10.1016/j.cell.2007.01.029
Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells, Molecular Cancer Therapeutics, vol.9, issue.4, pp.942-52, 2010. ,
DOI : 10.1158/1535-7163.MCT-09-0988
A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma, Blood, vol.91, issue.12, pp.4727-4764, 1998. ,
A new method for class prediction based on signed-rank algorithms applied to Affymetrix?? microarray experiments, BMC Bioinformatics, vol.9, issue.1, p.16, 2008. ,
DOI : 10.1186/1471-2105-9-16
URL : https://hal.archives-ouvertes.fr/inserm-00268075
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma, Leukemia & Lymphoma, vol.49, issue.3, pp.502-509, 2008. ,
DOI : 10.1158/1078-0432.CCR-03-0561
Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomibrefractory multiple myeloma (PANORAMA 2) Blood 1 1 8 : a b s t r a c t 8 1 4 ; o r a l presentation, 2011. ,
Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype, Leukemia, vol.91, issue.4, pp.925-956, 2013. ,
DOI : 10.1002/hep.23660
Update on a phase III study of panobinostat with bort-ezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1, Blood, vol.118, p.3976, 2011. ,
A phase IB, multi-center, open-label dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma, Blood, vol.114, p.3852, 2009. ,
IRF4 addiction in multiple myeloma, Nature, vol.403, issue.7201, pp.226-257, 2008. ,
DOI : 10.1038/nature07064
Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial, Blood, issue.114, p.480, 2011. ,
A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma, Blood, vol.112, p.2781, 2008. ,
Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases, Anticancer Res, vol.13, issue.4, pp.1091-1096, 1993. ,
Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data, The Open Bioinformatics Journal, vol.4, issue.1, pp.5-10, 2010. ,
DOI : 10.2174/1875036201004010005
Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells, J Immunol, vol.163, issue.1, pp.514-538, 1999. ,
A Novel Member of the I??B Family, Human I??B-??, Inhibits Transactivation of p65 and Its DNA Binding, Journal of Biological Chemistry, vol.281, issue.18, pp.12645-54, 2006. ,
DOI : 10.1074/jbc.M511956200
Cancer genes and the pathways they control, Nature Medicine, vol.1, issue.8, pp.789-99, 2004. ,
DOI : 10.1038/sj.onc.1207130
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma, Leukemia & Lymphoma, vol.29, issue.9, pp.1820-1823, 2012. ,
DOI : 10.1002/cncr.25584
Nuclear protein I??B-?? inhibits the activity of STAT3, Biochemical and Biophysical Research Communications, vol.387, issue.2, pp.348-52, 2009. ,
DOI : 10.1016/j.bbrc.2009.07.023
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma, Blood, vol.112, issue.10, pp.4235-4281, 2008. ,
DOI : 10.1182/blood-2007-10-119123
A Novel I??B Protein, I??B-??, Induced by Proinflammatory Stimuli, Negatively Regulates Nuclear Factor-??B in the Nuclei, Journal of Biological Chemistry, vol.276, issue.29, pp.27657-62, 2001. ,
DOI : 10.1074/jbc.M103426200
RNA-Binding Protein Quaking, a Critical Regulator of Colon Epithelial Differentiation and a Suppressor of Colon Cancer, Gastroenterology, vol.138, issue.1, pp.231-271, 2010. ,
DOI : 10.1053/j.gastro.2009.08.001
E2F1 and RNA binding protein QKI comprise a negative feedback in the cell cycle regulation, Cell Cycle, vol.10, issue.16, pp.2703-2716, 2011. ,
DOI : 10.4161/cc.10.16.15928
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A, J Biol Chem, vol.265, issue.28, pp.17174-17183, 1990. ,
The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006. ,
DOI : 10.1182/blood-2005-11-013458
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, issue.12, pp.3654-63, 1994. ,